Allogene Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALLO Nasdaq 2836 allogene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allogene Therapeutics, Inc.

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? - Jun 12th, 2025 9:30 am
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy - Jun 4th, 2025 10:00 am
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO - Jun 1st, 2025 8:45 am
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - May 23rd, 2025 6:30 am
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - May 22nd, 2025 3:17 pm
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - May 22nd, 2025 6:04 am
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - May 16th, 2025 4:36 am
Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays - May 15th, 2025 7:43 am
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - May 15th, 2025 7:35 am
Allogene's Q1 Earnings In Line With Estimates, Sales Nil - May 14th, 2025 4:29 am
Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - May 14th, 2025 1:18 am
Allogene Therapeutics: Q1 Earnings Snapshot - May 13th, 2025 2:11 pm
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update - May 13th, 2025 2:05 pm
Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030? - May 9th, 2025 6:26 am
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update - May 6th, 2025 6:30 am
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst institutional investors who own 59% - Apr 25th, 2025 5:20 am
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 23rd, 2025 8:12 am
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - Apr 8th, 2025 4:46 am
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - Apr 7th, 2025 6:30 am
Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Mar 15th, 2025 6:18 am